[Skip to Content]
[Skip to Content Landing]
April 29, 1974

Medical News

JAMA. 1974;228(5):551-560. doi:10.1001/jama.1974.03230300003001

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


Adriamycin effectiveness clouded by reports of cardiac toxicity  There always seems to be a Catch 22 in cancer therapy.No matter how bright the news, there is usually a qualifier.Perhaps it is this knowledge that makes cancer investigators and clinical oncologists what they seem to be: generally quiet, patient men and women.Consider the case of adriamycin, an Italian-developed drug that has been undergoing clinical trial in the United States for nearly four years.No drug shines brighter at the moment. There were at least a dozen presentations on adriamycin's clinical use at two recent and concurrent meetings in Houston; those of the American Association for Cancer Research and the American Society of Clinical Oncology.Still classified as investigational, adriamycin has now been used long enough and in enough patients to demonstrate truly remarkable results. A wide variety of neoplasms seem to yield to it, including cancers of